Tag:

Inspire Pharmaceuticals

Latest Headlines

Latest Headlines

Merck cuts 51 jobs as it closes Inspire site

On August 31, Merck will officially close the Raleigh, NC headquarters of Inspire Pharmaceuticals, an eye drug specialist that the company bought in April for $430 million. At the time of the

Merck plans to shutter Inspire HQ, axe staff as buyout closes

As Merck wraps up its purchase of the eye-drug specialist Inspire Pharmaceuticals, it's planning to close the company headquarters in North Carolina, cut jobs and relocate operations. It's unclear

Merck to close Inspire HQ, cut jobs

As Merck wraps up its purchase of the eye-drug specialist Inspire Pharmaceuticals, it's planning to close the company headquarters in North Carolina, cut jobs and relocate operations. It's unclear

Merck nabs eye specialist Inspire for $430M

Merck has inked a $430 million deal to buy Inspire Pharmaceuticals in a bid to expand its arsenal of meds for eye use. The cash offer of $5 per share has been approved by the boards of both

Merck snaps up Inspire's eye drugs in $430M buyout

Biotech IPOs may be hard to pull off, but buyouts are all the rage in the early part of 2011. And Merck ($MRK) joined the big game with today's announcement that it has struck a deal to acquire

Inspire slashes 65 jobs, drops failed CF drug in restructuring

Inspire Pharmaceuticals ($ISPH) says it will shelve its failed CF therapy denufosol and slash 65 workers from its payroll as it shifts its R&D focus to eye drugs. The cuts, 27 percent of its

Inspire shares tank after lead CF drug fails Ph3

Inspire Pharmaceuticals ($ISPH) started the biotech year with a bang as its share price exploded on the news that its cystic fibrosis drug denufosol failed the second of two Phase III clinical

Inspire scuttles eye drug and pencils new deal with Allergan

Seven months after reporting that its lead drug failed a late-stage trial, Durham, NC-based Inspire Pharmaceuticals has opted to shelve the dry eye therapy and recalculate its partnership deal with

Inspire Pharma R&D chief departs in shakeup

Inspire Pharmaceuticals' R&D chief is departing the company as the new CEO puts his stamp on the Durham, NC-based developer. Sepracor vet Adrian Adams was recently tapped to run the company, and

Inspire: Azasite doesn't meet goals in trials

North Carolina-based Inspire Pharmaceuticals announced this morning that Azasite, a drug already approved to treat conjunctivitis, failed to reach the main endpoint in two Phase II clinical trials